Greenwich LifeSciences Inc. Common Stock (GLSI)
Stock · NASDAQ · Health Care
$14.53as of 10/16/2026
Price chart
Active signals
GLSI Signal Track Record
How signals performed across all stocks →What GLSI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -1.6% | 48% | September 17, 2026 |
| Bollinger Band Breakdown | 23 | -7.0% | 35% | July 20, 2026 |
| Bollinger Band Breakout | 19 | -5.2% | 42% | August 17, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -4.5% | 38% | July 10, 2026 |
| Any 20-session window (baseline) | -2.1% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GLSI
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- greenwichlifesciences.com
Fundamentals
- 1-day range
- $15.11$15.55
- Market cap
- $209.02M
- P/E (trailing)
- —
- P/E (forward)
- -18.68
- EPS (trailing)
- $-1.53
- Dividend yield
- —
- Beta
- 1.54
- Avg. volume
- 144.6K
Forecasts
2 analyst ratings
Greenwich LifeSciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GLSIGreenwich LifeSciences Inc. Common Stock$14.55▼ 5.03%Market cap $209.02MP/E —$7.78$34.1
- MSLESatellos Bioscience Inc. Common Stock$6.46▼ 5.56%Market cap $209.77MP/E —$7.56$18.98
- KROSKeros Therapeutics Inc. Common Stock$10.66▼ 3.96%Market cap $211.16MP/E —$9.69$22.55
- NERVMinerva Neurosciences Inc Common Stock$2.35▼ 2.89%Market cap $206.85MP/E —$2.31$12.46
- ANTXAN2 Therapeutics Inc. Common Stock$3.38▼ 6.11%Market cap $218.98MP/E —$1$7.19
- IMUXImmunic Inc. Common Stock$6.97▼ 1.83%Market cap $198.06MP/E —$5.06$17.43
- NBPNovaBridge Biosciences American Depositary Shares$1.26▼ 2.33%Market cap $196.15MP/E —$1.26$6.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GLSI Greenwich LifeSciences Inc. Common Stock | $209.02M | — | $14.55 | ▼ 5.03% | $7.78$34.1 |
| MSLE Satellos Bioscience Inc. Common Stock | $209.77M | — | $6.46 | ▼ 5.56% | $7.56$18.98 |
| KROS Keros Therapeutics Inc. Common Stock | $211.16M | — | $10.66 | ▼ 3.96% | $9.69$22.55 |
| NERV Minerva Neurosciences Inc Common Stock | $206.85M | — | $2.35 | ▼ 2.89% | $2.31$12.46 |
| ANTX AN2 Therapeutics Inc. Common Stock | $218.98M | — | $3.38 | ▼ 6.11% | $1$7.19 |
| IMUX Immunic Inc. Common Stock | $198.06M | — | $6.97 | ▼ 1.83% | $5.06$17.43 |
| NBP NovaBridge Biosciences American Depositary Shares | $196.15M | — | $1.26 | ▼ 2.33% | $1.26$6.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 3 Clinical-Stage Cancer Stocks With Pristine Balance SheetsYahoo · 9/16/2026
Insider Activity
Insider Actions →- Patel Snehal · July 29, 2026 · Buy700 @ $13.1
- Patel Snehal · July 28, 2026 · Buy1.5K @ $13.59
- Patel Snehal · July 27, 2026 · Buy1.5K @ $13.62
- Patel Snehal · July 24, 2026 · Buy1.1K @ $12.88
- Patel Snehal · July 23, 2026 · Buy2.5K @ $13.14
Institutional Ownership
March 31, 2026
- Total shares held
- 1.60M
- Total value held
- $38.34M
- Institutional holders
- 60
- Unknown433.9K
- Unknown298.3K
- Unknown155.5K
- Unknown133.9K
- Unknown88.7K
- Unknown75.1K
- Unknown46.5K
- Unknown39.7K
- Unknown39.5K
- Unknown37.5K
See the full, filterable feed with live charts on the MarketWall dashboard.